Because VEGF-A is overexpressed in prostate cancer and is associated with poor prognosis, these findings suggest that angiogenesis is important in prostate cancer and that antiangiogenic therapy may be an effective treatment option for prostate cancer. The gene discussed is VEGFA; the disease is prostate carcinoma.